|
Pavlova M.G.
Vildagliptin – 15 years in active service with diabetologists
|
№2 / 2024
|
|
A.E. Bagriy, E.S. Mikhailichenko, A.V. Prikolota, K.E. Mogilevskaya
Features of the pathogenesis and treatment of diabetes mellitus during the COVID-19 pandemic
|
№11-12 / 2022
|
|
M.B. Antsiferov
EFFECT OF SGLT-2 INHIBITORS ON CARDIOVASCULAR OUTCOMES: REVIEW OF RESULTS OF CVD-REAL TRIAL
|
№16 / 2017
|
|
E.V. Biryukova
FIXED-DOSE COMBINATIONS IN THE THERAPY OF TYPE 2 DIABETES MELLITUS: THE WAY TO ACHIEVING GOOD GLYCEMIC CONTROL
|
№16 / 2017
|
|
N.A. Demidov (1), M.B. Antsiferov (2), L.G. Dorofeeva (2)
EFFICIENCY AND SAFETY OF USE OF CANAGLIFLOZIN IN THE OUTPATIENT PRACTICE
|
№5 / 2017
|
|
E.V. Biryukova
EMPAGLIFLOZIN: ENHANCEMENT OF POTENTIALS OF THE TREATMENT OF TYPE 2 DIABETES MELLITUS
|
№5 / 2016
|
|
E.E.Arinina, M.A.Rasheed, M. B. Antsiferov
Pharmacoeconomic Analysis Of Advantages Of Combined Incretin Therapy In Patients With Type 2 Diabetes Mellitus By The Example Of Vildagliptin
|
№5 / 2013
|
|
A.Yu.Mayorov
Algorithms Of Specialized Medical Care For Diabetic Patients 2011: Major Changes
|
№11 / 2012
|
Русский
